Security
SGMOQ · SANGAMO THERAPEUTICS, INC
SGMOQOTCCommon stockCurrentCIK 1001233Updated Sep 26, 2026
Name history
SANGAMO BIOSCIENCES INC · through Jan 6, 2017
SGMOQ price & chart
Loading TradingView…
OTC:SGMOQ on TradingView ↗About the company
Sangamo Therapeutics is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company is currently operating under court supervision in Chapter 11. To learn more, visit www.sangamo.com.
In the news
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO News provided by Pomerantz LLP Jan 28, 2025, 13:20 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigat ↗
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO News provided by Pomerantz LLP Jan 08, 2025, 12:00 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigati ↗
Recent filings
Bankruptcy or Receivership · Completion of Acquisition or Disposition of Assets
Items 1.03, 2.01, 9.01
Bankruptcy or Receivership · Completion of Acquisition or Disposition of Assets · Regulation FD Disclosure
Items 1.03, 2.01, 7.01, 9.01
Entry into a Material Definitive Agreement · Bankruptcy or Receivership
Items 1.01, 1.03, 9.01
NT 10-Q filing
SCHEDULE 13G/A filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Bankruptcy or Receivership · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 1.03, 3.01
Changes in Registrant's Certifying Accountant · Other Events
Items 4.01, 8.01, 9.01
Financial Statements and Exhibits
Items 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 59,745,000Source | 101,635,000Source | 165,320,000Source | 562,509,000Source |
| Property, Plant and Equipment, NetUSD | 11,042,000Source | 17,887,000Source | 26,874,000Source | 63,531,000Source |
| GoodwillUSD | — | 0Source | 0Source | 37,552,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 0Source | 0Source | 50,729,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,948,000Source | 41,918,000Source | 45,204,000Source | 100,444,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 371,000Source | 526,000Source | 923,000Source | 3,678,000Source |
| Assets, CurrentUSD | 35,830,000Source | 51,691,000Source | 94,328,000Source | 300,327,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,369,000Source | 5,175,000Source | 12,000,000Source | 18,223,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,064,000Source | 16,869,000Source | 25,991,000Source | 62,002,000Source |
| Other Assets, NoncurrentUSD | 871,000Source | 879,000Source | 16,627,000Source | 17,023,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 74,013,000Source | 78,865,000Source | 82,433,000Source | 267,551,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,507,000Source | 2,128,000Source | 1,781,000Source | 1,668,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,627,249,000Source | -1,504,317,000Source | -1,406,376,000Source | -1,148,545,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,464,000Source | -7,530,000Source | -4,595,000Source | -8,404,000Source |
| Stockholders' Equity Attributable to ParentUSD | -14,268,000Source | 22,770,000Source | 82,887,000Source | — |
| Additional Paid in Capital, Common StockUSD | 1,610,938,000Source | 1,532,489,000Source | 1,492,077,000Source | 1,450,239,000Source |
| Liabilities and EquityUSD | 59,745,000Source | 101,635,000Source | 165,320,000Source | 562,509,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 42,466,000Source | 45,805,000Source | 47,731,000Source | 111,711,000Source |
| Operating Lease, Liability, CurrentUSD | 1,702,000Source | 4,313,000Source | 4,589,000Source | 4,122,000Source |
| Accounts Payable, CurrentUSD | 14,437,000Source | 15,485,000Source | 15,259,000Source | 22,418,000Source |
| Operating Lease, Liability, NoncurrentUSD | 25,093,000Source | 26,253,000Source | 33,515,000Source | 38,986,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 0Source | 6,270,000Source |
| Other Liabilities, NoncurrentUSD | 580,000Source | 933,000Source | 1,187,000Source | 1,207,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,409,000Source | 8,195,000Source | 23,554,000Source | 16,007,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 81,000,000Source | 307,500,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 5,152,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -257,831,000Source | -192,278,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,961,000Source | 5,107,000Source | 15,065,000Source | 12,108,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,079,000Source | 12,382,000Source | 27,363,000Source | 31,650,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -155,000Source | -397,000Source | -2,755,000Source | -2,335,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | -6,335,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -97,208,000Source | -67,139,000Source | -224,842,000Source | -223,627,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -102,000Source | 37,524,000Source | 153,531,000Source | 59,285,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 102,000Source | 267,000Source | 21,155,000Source | 20,171,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 3,263,000Source | 904,000Source | 1,453,000Source | 2,104,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 70,749,000Source | 28,377,000Source | 14,588,000Source | 84,660,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -22,470,000Source | -3,286,000Source | -55,240,000Source | -78,428,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,948,000Source | 43,418,000Source | 46,704,000Source | 101,944,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,091,000Source | -2,048,000Source | 1,483,000Source | 1,254,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 9,079,000Source | 12,382,000Source | 27,363,000Source | 31,650,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 81,000,000Source | 307,500,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | — | — | — | 0Source |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | 0Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -3,700,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | 1,026,000Source | — | 0Source |
| General and Administrative ExpenseUSD | 34,886,000Source | 44,727,000Source | 61,167,000Source | 62,682,000Source |
| GoodwillUSD | — | 0Source | 0Source | 37,552,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | 0Source | 89,485,000Source | 0Source |
| Goodwill, Impairment LossUSD | — | 0Source | 38,138,000Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | 0Source | 51,347,000Source | — |
| Income Tax Expense (Benefit)USD | -568,000Source | -167,000Source | -5,072,000Source | 429,000Source |
| Investment Income, InterestUSD | 1,302,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -122,932,000Source | -97,941,000Source | -257,831,000Source | -192,278,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source |
| Operating ExpensesUSD | 160,791,000Source | 161,769,000Source | 450,237,000Source | 312,580,000Source |
| Operating Lease, ExpenseUSD | — | — | 9,400,000Source | 11,000,000Source |
| Operating Lease, Impairment LossUSD | — | 2,900,000Source | 28,900,000Source | — |
| Other Nonoperating Income (Expense)USD | -3,563,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 21,483,000Source | 7,132,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 39,552,000Source | 57,800,000Source | 176,232,000Source | 111,299,000Source |
| Operating Income (Loss)USD | -121,239,000Source | -103,969,000Source | -274,005,000Source | -201,281,000Source |
| Other Nonoperating Income (Expense)USD | -3,563,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -123,500,000Source | -98,108,000Source | -262,903,000Source | -191,849,000Source |
| Income Tax Expense (Benefit)USD | -568,000Source | -167,000Source | -5,072,000Source | 429,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -122,932,000Source | -97,941,000Source | -257,831,000Source | -192,278,000Source |
| Earnings Per Share, BasicUSD per share | -0.44Source | -0.49Source | -1.48Source | -1.25Source |
| Earnings Per Share, DilutedUSD per share | -0.44Source | -0.49Source | -1.48Source | -1.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 280,193,000Source | 201,699,000Source | 174,444,000Source | 154,345,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 280,193,000Source | 201,699,000Source | 174,444,000Source | 154,345,000Source |
| Additional Financial Items | ||||
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | 0Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -3,700,000Source | — | — | — |
| General and Administrative ExpenseUSD | 34,886,000Source | 44,727,000Source | 61,167,000Source | 62,682,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 38,138,000Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -123,969,000Source | -103,729,000Source | -173,375,000Source | -216,573,000Source |
| Interest and Other IncomeUSD | — | 5,861,000Source | 11,102,000Source | 9,432,000Source |
| Investment Income, InterestUSD | 1,302,000Source | — | — | — |
| Operating ExpensesUSD | 160,791,000Source | 161,769,000Source | 450,237,000Source | 312,580,000Source |
| Operating Lease, ExpenseUSD | — | — | 9,400,000Source | 11,000,000Source |
| Research and Development ExpenseUSD | 112,670,000Source | 111,521,000Source | 234,057,000Source | 249,898,000Source |
Filing attachments
tm2624942d1_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 tm2624942d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2026 Months Pending: 1 Industry Classification: 3254 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees (current): 73…
Read attachment ↗d125617dex991.htm · 8-K · 2026-08-13
EX-99.1 2 d125617dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SANGAMO THERAPEUTICS SELECTS SUCCESSFUL BIDDERS FOLLOWING COMPETITIVE ASSET AUCTION FOR $163.55 MILLION IN CASH CONSIDERATION AT CLOSING AND UP TO $100 MILLION IN POTENTIAL MILESTONES PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed sales subject to final approval by U.S. Bankruptcy …
Read attachment ↗d21956dex991.htm · 8-K · 2026-08-12
EX-99.1 2 d21956dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Case 26-10989-CTG Doc 268 Filed 08/06/26 Page 1 of 23 Docket #0238 Date Filed: 08/06/2026 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Case No. 26-10989 ─────────────────────────────────────────────────────────────── Debtor(s) Jointly Administered Monthly Operating Report …
Read attachment ↗d101629dex41.htm · 8-K · 2026-02-04
EX-4.1 3 d101629dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: February 4, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] This PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth …
Read attachment ↗d101629dex42.htm · 8-K · 2026-02-04
EX-4.2 4 d101629dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: February 4, 2026 (such date, the “Issue Date”) This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Da…
Read attachment ↗ny20048472x3_ex4-1.htm · 8-K · 2025-05-13
EX-4.1 3 ny20048472x3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC. Warrant Shares: Date of Issuance: May [ ], 2025 (such date, the “ Issue Date ”) Warrant No.: PF-[ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth …
Read attachment ↗